TG Therapeutics to Present at Upcoming Investor Conferences
May 27 2021 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its
participation at three upcoming virtual investor conferences.
Michael S. Weiss, the Company’s Executive Chairman and Chief
Executive Officer, is scheduled to participate in the following:
- Jefferies Virtual
Healthcare Conference: Fireside chat scheduled to take
place on Tuesday, June 1, 2021, at 2:00 PM ET
- Goldman Sachs
42nd Annual Global Healthcare
Conference: Fireside chat scheduled to take place on
Tuesday, June 8, 2021, at 1:20 PM ET
- Raymond James Human Health
Innovation Conference: Presentation scheduled to take
place on Tuesday, June 22, 2021, at 10:00 AM ET
A live webcast of each presentation will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at https://ir.tgtherapeutics.com/events.
Following each event, an archive file will be available for thirty
days.
ABOUT TG THERAPEUTICS, INC.TG
Therapeutics is a fully-integrated, commercial stage
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. In addition to an active research pipeline
including five investigational medicines across these therapeutic
areas, TG has received accelerated approval from
the U.S. FDA for UKONIQ® (umbralisib), for the
treatment of adult patients with relapsed/refractory marginal zone
lymphoma who have received at least one prior anti-CD20-based
regimen and relapsed/refractory follicular lymphoma who have
received at least three prior lines of systemic therapies.
Currently, the Company has three programs in Phase 3 development
for the treatment of patients with relapsing forms of multiple
sclerosis (RMS) and patients with chronic lymphocytic leukemia
(CLL) and several investigational medicines in Phase 1 clinical
development. For more information,
visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and Linkedin.UKONIQ® is a
registered trademark of TG Therapeutics, Inc.CONTACT:
|
Investor Relations |
|
Email: ir@tgtxinc.com |
|
Telephone: 1.877.575.TGTX (8489), Option 4 |
|
|
|
Media Relations: |
|
Email: media@tgtxinc.com |
|
Telephone: 1.877.575.TGTX (8489), Option 6 |
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Sep 2023 to Sep 2024